BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2018;3:790-802. [PMID: 30353856 DOI: 10.1016/S2468-1253(18)30265-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Anchang CG, Xu C, Raimondo MG, Atreya R, Maier A, Schett G, Zaburdaev V, Rauber S, Ramming A. The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases. Int J Mol Sci 2021;22:7506. [PMID: 34299122 DOI: 10.3390/ijms22147506] [Reference Citation Analysis]
2 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
3 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2-Inhibition: Potenzial bei der Behandlung chronisch-entzündlicher Immunerkrankungen. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34661350 DOI: 10.1111/ddg.14585_g] [Reference Citation Analysis]
4 Atreya R. Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy. Drug Res (Stuttg) 2021;71:S3-4. [PMID: 34788874 DOI: 10.1055/a-1606-4913] [Reference Citation Analysis]
5 Atreya R, Neurath MF. Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients? J Crohns Colitis 2021;15:697-8. [PMID: 33677523 DOI: 10.1093/ecco-jcc/jjab009] [Reference Citation Analysis]
6 Wang Z, Liu X, Cao F, Bellanti JA, Zhou J, Zheng SG. Prospects of the Use of Cell Therapy to Induce Immune Tolerance. Front Immunol 2020;11:792. [PMID: 32477335 DOI: 10.3389/fimmu.2020.00792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Chaparro M, Baston-Rey I, Fernández-Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, Argüelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Núñez Ortiz A, Charro M, Ginard D, Dueñas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutiérrez Casbas A, Ramírez de la Piscina P, Boscá-Watts MM, Arroyo M, García MJ, Hinojosa E, Gordillo J, Martínez Montiel P, Velayos Jiménez B, Quílez Ivorra C, Vázquez Morón JM, María Huguet J, González-Lama Y, Muñagorri Santos AI, Amo VM, Martín-Arranz MD, Bermejo F, Martínez Cadilla J, Rubín de Célix C, Fradejas Salazar P, San Román AL, Jiménez N, García López S, Figuerola A, Jiménez I, Martínez Cerezo FJ, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernández Camba A, García-Alonso FJ, Van Domselaar M, Pajares Villarroya R, Núñez A, Rodríguez Moranta F, Marín-Jiménez I, Robles Alonso V, Martín Rodríguez MDM, Camo-Monterde P, García Tercero I, Navarro Llavat M, Arias García L, Hervías Cruz D, Sulleiro S, Novella C, Vispo E, Barreiro-de Acosta M, Gisbert JP. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study. Inflamm Bowel Dis 2022:izab357. [PMID: 35166347 DOI: 10.1093/ibd/izab357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 . Kommentar. Dtsch Med Wochenschr 2022;147:222-3. [DOI: 10.1055/a-1710-7626] [Reference Citation Analysis]
9 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Reference Citation Analysis]
10 Breidert M, Eftekhari P, Louis F, Rotoiu C, Rath T, Neurath MF, Atreya R. Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients. Crohns Colitis 360 2020;2:otaa037. [PMID: 32776006 DOI: 10.1093/crocol/otaa037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cesario A, D'Oria M, Bove F, Privitera G, Boškoski I, Pedicino D, Boldrini L, Erra C, Loreti C, Liuzzo G, Crea F, Armuzzi A, Gasbarrini A, Calabresi P, Padua L, Costamagna G, Antonelli M, Valentini V, Auffray C, Scambia G. Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. J Pers Med 2021;11:265. [PMID: 33918214 DOI: 10.3390/jpm11040265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int 2022. [PMID: 35503130 DOI: 10.1007/s00296-022-05136-x] [Reference Citation Analysis]
13 Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
14 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Papoutsopoulou S, Burkitt MD, Bergey F, England H, Hough R, Schmidt L, Spiller DG, White MHR, Paszek P, Jackson DA, Martins Dos Santos VAP, Sellge G, Pritchard DM, Campbell BJ, Müller W, Probert CS. Macrophage-Specific NF-κB Activation Dynamics Can Segregate Inflammatory Bowel Disease Patients. Front Immunol 2019;10:2168. [PMID: 31572379 DOI: 10.3389/fimmu.2019.02168] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021;18:544-58. [PMID: 33712743 DOI: 10.1038/s41575-021-00424-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 Pathway in Crohn's Disease. Front Immunol 2021;12:622934. [PMID: 33859636 DOI: 10.3389/fimmu.2021.622934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Atreya R, Neurath MF. [Inflammatory bowel diseases - therapy update 2022]. Dtsch Med Wochenschr 2022;147:295-300. [PMID: 35291033 DOI: 10.1055/a-1585-4026] [Reference Citation Analysis]
20 Atreya R, Bojarski C, Kühl AA, Trajanoski Z, Neurath MF, Siegmund B. Ileal and colonic Crohn'´s disease: Ddoes location makes a difference in therapy efficacy? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100097] [Reference Citation Analysis]
21 Scarozza P, Schmitt H, Monteleone G, Neurath MF, Atreya R. Oligonucleotides-A Novel Promising Therapeutic Option for IBD. Front Pharmacol 2019;10:314. [PMID: 31068803 DOI: 10.3389/fphar.2019.00314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
22 Ruder B, Atreya R, Becker C. Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases. Int J Mol Sci 2019;20:E1887. [PMID: 30995806 DOI: 10.3390/ijms20081887] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
23 Schmitt H, Neufert C, Neurath MF, Atreya R. Resolution of Crohn's disease. Semin Immunopathol 2019;41:737-46. [PMID: 31552470 DOI: 10.1007/s00281-019-00756-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
24 Nguyen NH, Singh S, Sandborn WJ. Positioning Therapies in the Management of Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:1268-79. [PMID: 31676360 DOI: 10.1016/j.cgh.2019.10.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
25 Atreya R, Neurath MF. Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00217-4. [PMID: 34740616 DOI: 10.1016/j.jcmgh.2021.10.003] [Reference Citation Analysis]
26 Marin-Jimenez I, Bastida G, Forés A, Garcia-Planella E, Argüelles-Arias F, Sarasa P, Tagarro I, Fernández-Nistal A, Montoto C, Aguas M, Santos-Fernández J, Bosca-Watts MM, Ferreiro R, Merino O, Aldeguer X, Cortés X, Sicilia B, Mesonero F, Barreiro-de Acosta M. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study. BMJ Open Gastroenterol 2020;7:e000351. [PMID: 32337054 DOI: 10.1136/bmjgast-2019-000351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Chen G, Shen J. Artificial Intelligence Enhances Studies on Inflammatory Bowel Disease. Front Bioeng Biotechnol 2021;9:635764. [PMID: 34307315 DOI: 10.3389/fbioe.2021.635764] [Reference Citation Analysis]